Immunogenicity of COVID-19 vaccines and levels of SARS-CoV-2 neutralising antibody in the Bruneian population: Protocol for a national longitudinal study

Hazim Ghani ,1 Liyana Ahmad,1 Hanisah Sharif ,1 Justin Wong,1,2 Saifuddien Bagol,3 Mohammad Fathi Alikhani,4 Surita Taib,2 Chee Wah Tan,5 Feng Zhu ,1,5 Xin Mei Ong,3 Chin Yee Shim,4 Yan Wang,4 Si Yee Chan,4 Yuan Wei,4 Fazean Idris,1 Lin Naing,1 Lin-Fa Wang,5 Anne Catherine Cunningham1

ABSTRACT

Introduction Neutralising antibodies (NAbs) have been shown to be correlative of immune protection against SARS-CoV-2. We report the protocol for a national longitudinal study to assess and compare the level of NAbs generated in response to COVID-19 vaccines in Brunei Darussalam in adults 2–6 weeks post primary series (BBIBP-CoV, AZD1222, or mRNA-1273 vaccines) and their subsequent follow-up after administration of a third (booster-1) dose (BBIBP-CoV, mRNA-1273, or BNT162b2).

Methods and analysis Participant data will be extracted and processed from the national electronic health record system (Bru-HIMS) and the national mobile health application (BruHealth) into a research data platform. Eligible adults who have received their primary or booster vaccine will be invited using a stratified random sampling strategy based on age, gender and vaccine type (baseline target population, n=3000; 2–6 weeks post last dose). Blood serum will be isolated, and NAB levels assessed using the cPass surrogate virus neutralisation test. Baseline participants will then be screened for eligibility for subsequent longitudinal analysis. Those who have received a third dose will be followed up at 1, 3, 6, 9 and up to 12 months. NAB levels will be evaluated across the participant population according to vaccine platform/booster type, time since last dose and correlated with demographic data. The study period is from December 2021 to January 2023 and aims to evaluate how NAB levels wane following a third vaccine dose across different vaccine platforms and determine the impact and rate of breakthrough infections.

Ethics and dissemination This study has been approved by the Medical and Ethical Research Committee of Ministry of Health, Brunei Darussalam. Individual NAB test results will be shared with each participant by text message. The findings from this study will help policy-makers in Brunei develop future vaccination strategies and establish regulations across multiple agencies.

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ Three vaccine platforms used for primary series vaccination can be compared (BBIBP-CoV (whole inactivated virus), AZD1222 (viral vector), and mRNA-1273 or BNT162b2 (mRNA) with and without a third (booster-1) dose.
⇒ Stratified random sampling and recruitment of adults across 5 age groups with a target of 3000 participants across vaccine platforms and controlled sampling time points.
⇒ Neutralising antibodies alone are not absolute correlates of protection against infection, disease severity and death, and the cPass SARS-CoV-2 Neutralization Antibody Detection Kit only measures antibodies against the ancestral SARS-CoV-2 strain (Wu01).
⇒ Limited information on prevaccination neutralising antibody levels and immunogenicity generated from homologous vaccinations using AZD1222 and BNT162b2.
⇒ Breakthrough infections are determined based on positive PCR or Antigen Rapid Test results and are not individually sequenced, which restricts data on the causative SARS-CoV-2 variant.

INTRODUCTION and rationale

Vaccination has been instrumental in emerging from the restrictions introduced globally in response to the COVID-19 pandemic. The first year of the pandemic led to unprecedented breakthroughs in vaccine technology and new platforms, for example, viral vector (AZD1222 developed by Oxford-AstraZeneca) and mRNA vaccines (mRNA-1273 from Moderna, and BNT162b2 developed by Pfizer-BioNTech) have been approved for human use. Traditional whole
inactivated virus vaccines have also been developed (eg, BBIBP-CorV manufactured by Sinopharm). Immunity develops following exposure to a pathogen, and vaccines aim to mimic this by inducing a primary immune response. This results in a rapid secondary immune response to the wild-type pathogen which prevents the development of infection and/or serious illness.\(^\text{7,8}\)

It is, therefore, of great interest to monitor immune responses to the various vaccine preparations in populations to evaluate the effectiveness of these vaccination programmes.\(^\text{9}\) There is evidence that antibody measurements can be used as a correlate of protection post vaccination.\(^\text{10}\) Antibodies can be isolated from whole blood and subsequently analysed for specificity and functional properties. Total antibodies specific to SARS-CoV-2 are typically detectable within 2 weeks after vaccination and can persist for several months but are likely to wane over time.\(^\text{11-14}\)

Neutralising antibodies (NAbs) are functionally antiviral in that they bind to the virus spike protein and block viral entry to host cells. High level of NAbs have been correlated with survival\(^\text{15,16}\) and appear to be the best measure of vaccine efficacy.\(^\text{17}\) Surrogate virus neutralisation assays in the form of competitive ELISA have been developed and validated to determine specific functional antibodies that can inhibit the interaction of viral receptor-binding domain (RBD) proteins with human ACE 2 (hACE2) receptors.\(^\text{18}\) Commercially available NAb preparations have been authorised for treatment and are particularly useful in immunocompromised individuals.\(^\text{19}\) There is much interest in whether NAb generated by one variant (or vaccine type) can protect against future variants of concern.\(^\text{20}\)

The COVID-19 pandemic in Brunei Darussalam (pop. 430 000) has been characterised by distinct waves. The first wave, in March 2020, was largely import driven and successfully contained within a month. This was followed by a period of relative stability, with no domestic cases reported for over a year due to strict international travel restrictions.\(^\text{21}\) The second wave commenced in August 2021 and was predominantly caused by the Delta variant with more than 15 000 local cases with only a small proportion of imported cases reported from August until December 2021. Subsequent waves in 2022 have been driven by the Omicron subvariants BA.2 and BA.5.

Brunei Darussalam introduced the National Vaccination Programme on 3 April 2021 with vaccine administration implemented in three phases. The first phase covered healthcare and frontline workers, and individuals aged 60 years and above; the second phase for individuals with chronic diseases; and the third phase for the general public comprising adults aged 18 years and above. Three different vaccine types were distributed for the primary immunisation series: BBIBP-CorV (whole inactivated virus), AZD1222 (viral vector) and mRNA-1273 (mRNA) were offered to adults. This was followed by a booster dose of either BBIBP-CorV, mRNA-1273, or BNT162b2 (mRNA) administered at least 3 months following completion of the primary series. Vaccination for adolescents aged 12 years and above commenced in November 2021 using the BNT162b2 vaccine and they are not included in this study population.

The pandemic catalysed the development of a national mobile health application, BruHealth (EYVD Technology Limited), launched by the Ministry of Health (MOH), Brunei Darussalam, in May 2020. This provides a virtual health management platform with digital contact tracing, a premise scan QR code function in public spaces, self-test reporting and vaccination appointment capabilities. BruHealth integrates with the Brunei Health Information System (Bru-HIMS), which links primary and secondary healthcare data across the entire government health network. Both platforms will be used accordingly for the conduct of this study.

**Aims and objectives**

Currently, limited data exist on the comparative immunogenicity of different COVID-19 vaccines in Southeast Asian populations. Thus, our study aims to assess the level of NAbs generated by primary (two) doses of the BBIBP-CorV, AZD1222 and mRNA-1273 vaccines in the vaccinated Bruneian population and to compare their immunogenicity. In addition, this study captures participants who have received a third (booster-1) dose of either BBIBP-CorV, mRNA-1273 or BNT162b2. Durability of NAbs and rate of breakthrough infections will also be investigated over a period of 1 year. Furthermore, our study will allow the evaluation of the effects of a heterologous booster dose on NAb levels in the study cohort. This will provide new information on immune responses in a Southeast Asian population and provide data on any differences in NAb levels across different age groups, gender and vaccine types. This is the first instance where the national electronic health record system (Bru-HIMS) is integrated with the local BruHealth application for the evaluation of NAb levels across the Bruneian population.

**METHODS**

**Study design**

This study is designed to assess the immune response generated in adult Bruneian population who have been vaccinated with BBIBP-CorV, AZD1222 or mRNA-1273 (primary series), and BBIBP-CorV, mRNA-1273, or BNT162b2 (booster-1). NAb levels will be analysed across the participant population according to vaccine platforms and associated with sociodemographic data. There are two phases to this study: phase 1 is a baseline study to compare the level of NAbs induced by each primary series vaccine platform with and without a booster dose across the Bruneian population; phase 2 is a longitudinal study to evaluate the potential effects of waning and breakthrough infection following primary series plus one booster dose on NAb levels over a period of a year. Individuals who had a confirmed COVID-19 diagnosis prior to the first blood withdrawal will be excluded from the
study. The overview of the participant events and timeline is summarised in table 1.

**Study settings**
Vaccinated members of the general adult population will be recruited to this study. Blood sampling and serum isolation will take place in PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam for phase 1 (baseline) of the study and Phlebotomy Services, Central Specimen Receiving Area, Department of Laboratory Services (DLS) at RIPAS Hospital, Brunei Darussalam for phase 2 (longitudinal follow-up). NAb level measurement will be conducted in Duke-NUS Medical School, Singapore for phase 1, and DLS, RIPAS Hospital, Brunei Darussalam for phase 2.

**Eligibility criteria**

**Inclusion criteria**
Participants will be included in the study if they meet the following criteria:
1. Aged 18 years and above.
2. Vaccinated with either the BBIBP-CorV, AZD1222, or mRNA-1273, with or without an additional booster dose (BBIBP-CorV, mRNA-1273, or BNT162b2) for phase 1. Phase 2 will follow-up on participants who have received a booster dose over a period of 1 year.

**Exclusion criteria**
Participants will be excluded from the study if they meet any of the following criteria:
1. History of travel between the first dose and first blood withdrawal in phase 1.

**Outcomes**
The level of NAbs in the serum samples will be assessed using the cPass SARS-CoV-2 Neutralization Antibody Detection Kit (GenScript Biotech, China) according to the manufacturer’s protocol. Presence of NAbs can be categorised as either positive (> 30%) or negative (< 30%) based on percentage inhibition of viral RBD binding to hACE2 receptor. NAb levels will be analysed across the participant population according to vaccine platform/booster type, time since the last dose and associated with sociodemographic data. This analysis will advise policymakers in Brunei on future vaccination strategies and establishing regulations across multiple agencies.

**Sample size**
The sample size determined for each primary vaccination platform, that is, BBIBP-CorV, AZD1222, and mRNA-1273 was 1000 for the phase 1 study (total n=3000). Individuals will be randomly selected, stratified by four categories: (1) the three primary vaccination series platform; (2) gender; (3) age groups, that is, 18–30, 31–40, 41–50, 51–60, and above 60 years old; and (4) duration post vaccination (primary or booster immunisation), that is, 2, 3, 4, 5 and 6 weeks after receiving the primary or booster doses.

Considering the outcome variable for NAb measurement as positive or negative, the targeted sample size of 1000 would give a precision of 2% for an expected positive rate of 88%, though the positive rate is expected to be much higher. The sample size could give a precision of 3% if the positive rate is 63%. In a comparison of the positive rate, a sample size of 100 could detect a difference of 5% between two groups, with a power of 99% for two positive rates of 90% vs 95%; a power of 84% for two positive rates of 80% vs 85%, and a power of 71% for two positive rates of 70% versus 75%. As we anticipate a higher positive rate, for example, at least higher than 80%, the targeted sample size is considered more than adequate. In terms of the phase 2 study, a sample size of 160 participants for each vaccine category will achieve a precision of at least 20% of SD (a small effect size) in estimating the mean values for each time point after the baseline (2–6 weeks post the last dose). In comparing groups of n=160 for each category, a significant result can be obtained with a mean difference of at least 36% of SD (small to medium effect size), with a power of 80%. Sample size calculation was done using PS: Power and Sample Size Calculation software (V.3.1.6).

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Participant event and timeline</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Timepoint (post last dose)</strong></td>
<td><strong>Phase 1</strong></td>
</tr>
<tr>
<td>2–6 weeks</td>
<td>1 month</td>
</tr>
<tr>
<td>Eligibility screening</td>
<td>x</td>
</tr>
<tr>
<td>Allocation</td>
<td>x</td>
</tr>
<tr>
<td>Informed consent</td>
<td>x</td>
</tr>
<tr>
<td>Sociodemographic data</td>
<td>x</td>
</tr>
<tr>
<td>COVID-19 vaccination history</td>
<td>x</td>
</tr>
<tr>
<td>Medical history</td>
<td>x</td>
</tr>
<tr>
<td>Drug history</td>
<td>x</td>
</tr>
<tr>
<td>Blood samples</td>
<td>x</td>
</tr>
<tr>
<td>COVID-19 breakthrough infection history</td>
<td>x</td>
</tr>
</tbody>
</table>
Participant identities will be verified on-site at the blood sampling centre. The PIS containing the study design and purpose will be explained to all participants. Written consent will be subsequently obtained prior to sampling. Sociodemographic data including age, gender, ethnicity, comorbidities (i.e., diabetes mellitus, chronic kidney disease, hypertension, ischaemic heart disease and cancer) and immunosuppressive drug use will be enquired and recorded in a secured online platform (EVYDResearch, EVYD Technology Limited, Singapore). For phase 2, participants with history of COVID-19 breakthrough infection (determined via either positive PCR or Antigen Rapid Test results), if any, will be documented. The symptoms and severity of breakthrough infections in these participants may be analysed and compared with those without breakthrough infections.

Recruitment and allocation
Eligible participants who are within 2–6 weeks after their last vaccination will be identified from the BruHealth database and invited on a weekly basis in the phase 1 study. The phase 2 study will follow up on participants who had received the third booster dose and sampled at 1, 3, 6, 9 and up to 12 months following the booster dose. The number of participants invited for both study phases is dependent on the target recruitment according to the maximum capacity of the blood sampling centre, with an assumed response rate evaluated on a weekly basis. A balance in sample size for each stratum by age group, gender and vaccine platform will be included in the weekly target.

Potential participants will be sent three text messages for recruitment into the study in both English (table 2) and native Malay languages. The first text message will be an invitation to participate in the study. The second text message acts as a reminder and will be sent the following day to prompt response to the invitation. Both text messages will contain a blood withdrawal appointment date and time with a link to an online form (Qualtrics XM, Qualtrics International, USA), participant information sheet (PIS) and an option to agree or disagree to join the study. Those who agree will be sent a third text message 24 hours before their allocated appointment date. Individuals who do not agree will not be included in the study.

Blood sampling and serum analysis
A whole blood sample of 5 mL will be drawn from each participant by venipuncture and allowed to incubate at room temperature for 15–30 min to allow clotting. Serum will be separated by centrifugation at 1000–2000 g for 10 min. Serum samples will be isolated and stored at −20°C.

The level of NAb in the serum samples will be assessed using the cPass SARS-CoV-2 Neutralization Antibody Detection Kit (GenScript Biotech, China) according to the manufacturer’s protocol. Briefly, 20 µL of serum sample, positive and negative controls will be diluted in the buffer (volume ratio of 1:9) and an equal volume of horse-radish peroxidase (HRP)-RBD solution will be added. The mixture will be incubated at 37°C for 30 min before being added to a capture plate which will be further incubated for 15 min at 37°C. The plate will be washed using a diluted washing buffer solution four times and 100 µL of 3,3',5,5'-tetramethylbenzidine solution will be added to each well. This will be followed by incubation in the dark at room temperature for 15 min, before the addition of 50 µL of stop solution to each well to stop the enzymatic reaction. The absorbance value (optical density, OD) of each well will be read using a microplate reader at 450 nm wavelength. The level of NAb in the serum samples will be measured by calculating the percentage signal inhibition as shown below. Serum samples with inhibition of at least 30% will be considered as positive for the presence of NAbs, as stated in the kit instructions. Percentage

<table>
<thead>
<tr>
<th>Text message type</th>
<th>Text content</th>
</tr>
</thead>
<tbody>
<tr>
<td>First (invitation)</td>
<td>[MOH] IC:01234567. You are invited to the next phase of the vaccine research study on dd/mm/yy at hh:mm - hh:mm. This will measure the status of your antibody level after vaccination. Please respond at bit.ly/abcedfgh by Wednesday, 5:00 PM. Thank you.</td>
</tr>
<tr>
<td>Second (invitation reminder)</td>
<td>[MOH] IC:01234567. dd/mm/yy hh:mm - hh:mm. An antibody test is reserved for you next week. Please confirm your attendance at bit.ly/abcedfgh by Wednesday, 05:00 PM. Thank you for your support. Please disregard this message if you have already responded.</td>
</tr>
<tr>
<td>Third (appointment reminder)</td>
<td>[MOH] IC:01234567. Reminder for your appointment tomorrow at Central Receiving Area (CSRA), RIPAS Hospital on dd/mm/yy at hh:mm - hh:mm. Location: bit.ly/tuvwxyz.</td>
</tr>
</tbody>
</table>

bit.ly/abcedfgh, custom link to online form; bit.ly/tuvwxyz, custom link for directions to blood sampling centre; dd/mm/yy, allocated date; hh:mm, allocated time; IC, Identity Card number; MOH, Ministry of Health.
inhibition will be converted to antibody titres expressed in international units per millilitre (IU/mL) using a WHO International Standard conversion tool. Antibody titres will be log-transformed before statistical analyses and presented as geometric mean titres (GMT).

\[
\% \text{ Signal inhibition} = \left(1 - \frac{\text{OD value of serum sample}}{\text{OD value of negative control}}\right) \times 100\%
\]

The results of the NAb measurement as positive or negative and in IU/mL will be disseminated to all participants via a text message. A custom link for additional information on the interpretation of NAb levels will be provided should the participant require further information and to address any enquiry.

Retention
All data recorded and stored on the online platform (EVYDResearch) will only be stored for the duration of the study. Following cessation of the study, data will be securely deleted and disposed of in accordance to EVYD Technology Limited’s Data Retention Framework.

Data management and confidentiality
Data confidentiality will be maintained through the online platform and only the research team will have access to full participant information. MOH, Brunei Darussalam will retain ownership of the participant data on Bru-HIMS and BruHealth and hold the rights to grant access to authorised personnel for the purposes of conducting the research. EVYDResearch platform follows the data security and privacy requirement as set forth by MOH, Brunei Darussalam. There is a management system for the platform administrator to distribute or withdraw permission for authorised users. The platform administrator will grant access to the relevant fields as permitted by MOH, Brunei Darussalam. Authorised users will be required to sign the Officials Secret Act and to maintain participant confidentiality at all times. The platform strictly abides by the Data Privacy Policy in the collection, usage and disclosure of participant data. In accordance with Health Insurance Portability and Accountability Act Privacy Rule, all identifiers of the individual will be removed using the Safe Harbor method.

Statistical methods
Sociodemographic variables, medical and drug history will be used to produce visualisation plots and descriptive statistics and simple univariate analyses will be performed. Statistical software including RStudio (RStudio, Massachusetts, USA) and GraphPad Prism (GraphPad, California, USA) may be used when necessary for advanced statistical analyses and data visualisation.

The NAb levels, based on percentage inhibition and GMT, elicited by each vaccine platform or subgroup (e.g., by post-vaccination week, by gender, by age group) will be analysed using the Mann-Whitney U and Kruskal-Wallis tests with 95% CI. Comparison of positive rates will be analysed by binomial regression using binreg R package (RStudio) and presented with positive rate ratios, their 95% CIs and p values. P value of less than 0.05 will be considered statistically significant.

Patient and public involvement
No patient involved.

ETHICS AND DISSEMINATION

Research ethics approval
This study is approved by the Medical and Ethical Research Committee (MHREC) of MOH, Brunei Darussalam (Reference No: MHREC/MOH/2021/14(1) dated 18 November 2021). The study will be conducted in conformance with the Good Clinical and Laboratory Practice.

Informed consent process
All participants will give written informed consent to participate in this study. PIS will be provided to all participants in their preferred language (English, Malay or Chinese). The PIS will contain all relevant information relating to the study, potential risks and benefits, confidentiality and contact details should further information be required. The PIS will also be explained verbally on-site by research assistants and queries will be addressed. Participants will acknowledge that they understand the PIS and are free to withdraw from the study at any time. They will agree to their medical records being accessed and their blood being withdrawn for the purpose of this study. In addition, consent will be obtained for the use of serum sample for other similar purposes for example, for better antibody measurement techniques or against future emerging SARS-CoV-2 variants. Participants may agree to the first (current study) but not the second (future relevant studies), if they wish. A physical, hard copy signed consent form will be collected from each participant prior to blood withdrawal. No remuneration will be provided in exchange for their participation.

Access to data
Collected data will be secured against unauthorised access and will be stored securely on the online platform.

Dissemination
Study findings will be disseminated to all participants. The results of the study will be submitted for publications in peer-reviewed journals as they become available. The data will also be presented internally to MOH, Brunei Darussalam, universities and in national and international scientific conferences and seminars.

Author affiliations

1PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Gadong, Brunei Darussalam
2Disease Control Division, Ministry of Health Brunei Darussalam, Bandar Seri Begawan, Brunei-Muara, Brunei Darussalam
3Department of Laboratory Services, Ministry of Health Brunei Darussalam, Bandar Seri Begawan, Brunei-Muara, Brunei Darussalam
4EVYD Research Pte Ltd, A Subsidiary of EVYD Technology Limited, Singapore
Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore

Contributors All authors have contributed to the study design and conceptualisation, writing and critical revision of the manuscript. HG, LA, HS, JW, SB, MFA, ST, CY5, YW, SYC, YW, FI, LN and ACC will manage the recruitment of study participants, data coordination and blood withdrawal. CWT, FZ, XMO and LFW will manage NAb measurement. All authors read and approved the final manuscript.

Funding This research is funded by the Council for Research and the Advancement of Technology and Science (CREATEs), Ministry of Transport and Infocommunications, Brunei Darussalam (Grant No.: UBD/RSCH/MITC-CREATEs/001) and Temasek Foundation, Singapore (Grant No.: N/A).

Competing interests CWT and LFW received a patent for the development of the cPass SARS-CoV-2 Neutralization Antibody Detection Kit used in the study. CY5, YW, SYC and YW are employed by EYVD Technology, who is the provider for the BruHealth and EYVDResearch platforms.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Hazim Ghani http://orcid.org/0000-0002-3383-8403
Hanisah Sharif http://orcid.org/0000-0002-2620-906X
Feng Zhu http://orcid.org/0000-0002-8131-1219

REFERENCES